F.D.A. Confirms Widespread Shortages of Adderall
In a landmark decision Friday, the U.S. Food and Drug Administration said it had confirmed that the drug, which is approved by the agency to treat ADHD, was experiencing a widespread shortage.
The decision, made by an F.D.A. panel of experts, could slow the introduction of the drug in the United States and is likely to cause more problems for those who had purchased it illegally.
The shortage, affecting some 1 million prescriptions a day, has contributed to a crisis facing the drug industry, as some brand-name drugs that once brought in $600 million a year have plummeted, leading many to question the efficacy of the generic versions.